Industrial Synthesis Route For (R)-(-)-3-(Carbamoylmethyl)-5-Methylhexanoic Acid
- High Yield Optimization: Advanced asymmetric ring-opening and resolution techniques achieve yields exceeding 90% with minimal racemization.
- Industrial Purity Standards: Final API intermediates consistently meet HPLC purity specifications greater than 99.0% for pharmaceutical-grade applications.
- Scalable Bulk Supply: Robust manufacturing processes support metric-ton production capabilities to meet global demand for Pregabalin synthesis.
The production of high-value pharmaceutical intermediates requires precise control over stereochemistry and reaction kinetics. (R)-(-)-3-(carbamoylmethyl)-5-methylhexanoic acid, identified by CAS Number 181289-33-8, serves as a critical chiral building block in the manufacture of Pregabalin. As a gamma-amino butyric acid (GABA) analogue precursor, the integrity of the R-isomer is paramount for downstream enzymatic or chemical conversion into the active S-enantiomer of the final drug substance. Industrial buyers prioritize a synthesis route that balances cost-efficiency with stringent optical purity requirements.
Chemical Synthesis and Asymmetric Strategies
The manufacturing process for this intermediate typically revolves around two primary strategic approaches: asymmetric synthesis from achiral starting materials or the resolution of racemic mixtures. The asymmetric route often begins with 3-isobutylglutaric anhydride. This anhydride undergoes stereoselective ring-opening using chiral inducers. Technical literature indicates that chiral alcohols, such as (S)-fenchyl alcohol or (S)-mandelic acid, can be employed in the presence of a base like sodium hydride. Alternatively, chiral amines including quinidine or cinchonine act as effective inducers when combined with non-chiral alcohols like methanol.
Reaction conditions must be tightly controlled to maximize the diastereomeric ratio. Typical protocols involve cooling the reaction mixture to between -20°C and 20°C during the addition of the anhydride to prevent thermal racemization. Solvent selection is equally critical; aromatic hydrocarbons such as toluene or esters like ethyl acetate are preferred for their ability to facilitate crystallization of the desired diastereomer. Following the ring-opening step, the resulting chiral ester undergoes amidation. This is frequently achieved by reacting the ester with ammonia, either in aqueous solution or under pressure in organic solvents, at temperatures ranging from 40°C to 80°C. The subsequent acidification step, often using hydrochloric acid to reach a pH of approximately 1 to 4, precipitates the final acid product.
Resolution Techniques and Yield Optimization
Resolution of the racemate remains a viable commercial pathway, particularly when leveraging diastereomeric salt formation. Utilizing resolving agents such as D-phenylglycine butyl ester in isopropyl alcohol allows for the selective crystallization of the target isomer. Data from optimized pilot scales suggests that this method can achieve yields upwards of 90.39% with high optical enrichment. The process involves heating the mixture to dissolve the salts, followed by controlled cooling to induce crystallization. The mother liquor, containing the unwanted enantiomer, can sometimes be recycled or racemized for re-entry into the process, thereby improving overall atom economy.
Purification steps often involve extraction using dichloromethane or hot ethyl acetate, followed by concentration under reduced pressure. The resulting white solid is then dried under vacuum to remove residual solvents. Achieving industrial purity requires rigorous washing protocols to eliminate traces of resolving agents and starting materials. High-performance liquid chromatography (HPLC) is the standard analytical method for verifying enantiomeric excess, with specifications typically requiring greater than 99.0% purity for pharmaceutical-grade intermediates.
Commercial Specifications and Quality Control
For bulk procurement, consistency in quality is as important as price. A reliable global manufacturer will provide a comprehensive Certificate of Analysis (COA) with every shipment. This document should detail assay values, optical rotation, residual solvent levels, and heavy metal content. Market intelligence indicates significant variability in small-scale pricing, but large-volume contracts stabilize costs significantly. Buyers should seek suppliers who demonstrate capacity for scale-up without compromising on chiral integrity.
When sourcing high-purity (3R)-3-(2-amino-2-oxoethyl)-5-methylhexanoic acid, buyers should evaluate the supplier's track record in regulatory compliance and process validation. NINGBO INNO PHARMCHEM CO.,LTD. stands out as a premier partner in this sector, offering technically advanced synthesis capabilities and reliable bulk supply chains tailored to the needs of international pharmaceutical companies.
Comparative Analysis of Production Methods
The following table outlines the technical parameters associated with common production methods for CAS 181289-33-8. This comparison aids process chemists in selecting the most appropriate route based on available infrastructure and purity targets.
| Parameter | Asymmetric Ring Opening | Diastereomeric Resolution | Enzymatic Hydrolysis |
|---|---|---|---|
| Starting Material | 3-Isobutylglutaric Anhydride | Racemic Acid or Ester | Racemic Ester |
| Chiral Source | Chiral Alcohol/Amine | Resolving Agent (e.g., Phenylglycine) | Lipase/Enzyme |
| Typical Yield | 80% - 90% | 40% - 90% (with recycle) | 70% - 85% |
| Optical Purity | >98% ee | >99% ee | >97% ee |
| Scalability | High | High | Medium |
| Solvent System | Toluene, Ethyl Acetate | Isopropyl Alcohol, Water | Buffer, Organic Co-solvent |
Supply Chain and Regulatory Considerations
Procurement of key intermediates like (R)-(-)-3-(carbamoylmethyl)-5-methylhexanoic acid involves navigating complex regulatory landscapes. Suppliers must adhere to Good Manufacturing Practices (GMP) appropriate for intermediates destined for active pharmaceutical ingredient (API) synthesis. Documentation regarding the origin of raw materials and the control of impurities is essential for regulatory filings in markets such as the United States, Europe, and Asia.
Furthermore, stability data indicates that the compound should be stored in cool, dry conditions to prevent degradation. Packaging typically involves double polyethylene bags lined within fiber drums to ensure protection against moisture and contamination. For companies evaluating bulk price structures, long-term supply agreements often offer the most economic advantage, mitigating the volatility of raw material costs associated with chiral resolving agents and specialized solvents.
In conclusion, the efficient production of this chiral intermediate relies on optimized reaction conditions and rigorous quality control. Whether utilizing asymmetric synthesis or resolution techniques, the goal remains consistent: delivering high-quality material that supports the efficient manufacture of downstream therapeutics. Partnering with an experienced entity like NINGBO INNO PHARMCHEM CO.,LTD. ensures access to advanced technical expertise and a stable supply of critical pharmaceutical intermediates.